Results 21 to 30 of about 1,115 (163)

Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies

International Journal of Hepatology, 2020
Aims. Thrombocytopenia complicates the management of patients with chronic liver disease (CLD) undergoing invasive procedures with a bleeding risk. Until recently, prophylactic platelet transfusion was the only treatment option, but has significant ...
Fred Poordad, Norah A. Terrault, Naim Alkhouri, Wei Tian, Lee F. Allen, Mordechai Rabinovitz   +5 more
doaj   +2 more sources

Avatrombopag for the Treatment of Thrombocytopenia Post Hematopoietic Stem-Cell Transplantation

Therapeutic Advances in Hematology, 2022
Background: Thrombocytopenia post hematopoietic stem-cell transplantation (HCT) usually contributes to poor outcomes with no standardized treatment. Eltrombopag and romiplostim can be feasible for post-HCT thrombocytopenia, but the use of avatrombopag ...
Ziyan Zhang, Yue Han, Chengyuan Gu
exaly   +2 more sources

Efficacy and Safety of Avatrombopag in Patients With Thrombocytopenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Frontiers in Pharmacology, 2019
Background: Avatrombopag is a novel oral, nonpeptide thrombopoietin receptor agonist (TPO-RA). A few studies have shown that avatrombopag is effective against thrombocytopenia.
Wenjun Zou, Jianming Wu, Dalian Qin
exaly   +3 more sources

Avatrombopag for the Treatment of Adult Patients With Chronic Immune Thrombocytopenia (cITP): Focus on Patient Selection and Perspectives

Therapeutics and Clinical Risk Management, 2022
Galina Tsykunova,1– 3 Waleed Ghanima2– 4 1Department of Hematology, Haukeland University Hospital, Bergen, Norway; 2Institute of Clinical Medicine, University of Oslo, Oslo, Norway; 3Department of Hemato-Oncology, Østfold Hospital, Grålum, Norway ...
Galina Tsykunova
exaly   +2 more sources

Avatrombopag improves thrombocytopenia in MYH9-related disorder following eltrombopag treatment failure

Platelets, 2022
MYH9-related disorder (MYH9-RD) is autosomal dominant thrombocytopenia caused by mutations in the MYH9 gene, which codes for the non-muscle myosin-IIA heavy chain. We present a case of a 24-year-old Chinese man with MYH9-RD who was initially misdiagnosed
Abdul Rehman Arif, Miaomiao Zhao, Wenlan Chen, Mei Xue, Shanshan Luo, Yadan Wang   +5 more
doaj   +2 more sources

Efficacy and safety of different TPO-RAs combined with cyclosporine in the treatment of NSAA [PDF]

Therapeutic Advances in Hematology
Background TPO receptor agonists (TPO-RAs) have significantly improved the treatment outcomes of patients with aplastic anemia. Currently, three small-molecule TPO-RAs (eltrombopag, hetrombopag, and avatrombopag) are available for clinical use and work ...
Ting Wang, Boyi Wang, Donglan Liu, Nianbin Li, Shuai Gao, Huaquan Wang, Lijuan Li, Limin Xing, Hong Liu, Guojin Wang, Yuhong Wu, Wen Qu, Jia Song, Jing Guan, Zonghong Shao, Rong Fu   +15 more
doaj   +2 more sources

Avatrombopag and Platelet Recovery in Sepsis-Associated Thrombocytopenia: A Retrospective Observational Cohort Study [PDF]

Clinical and Applied Thrombosis/Hemostasis
Background Sepsis-associated thrombocytopenia (SAT) is a common complication in critically ill patients and is associated with increased disease severity and adverse outcomes.
Nengxian Shi MS, Jin He MS, Qian Xu MS, Xin Zhao MD, Yunying Bao MD, Dan He BS, Yucheng Li BS, Hongbin Hu MD, Zhenhua Zeng PhD, Ranghui Yu MS, Qiang Wei MD   +10 more
doaj   +2 more sources

The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK

Journal of Market Access & Health Policy
Background: Thrombopoietin receptor agonists—romiplostim, eltrombopag and avatrombopag—are commonly used as second-line treatments for immune thrombocytopenia (ITP).
Nichola Cooper, Sebastian Guterres, Michał Pochopień, Koo Wilson, Sam James, Mondher Toumi, Anna Tytuła, Carly Rich, Daniel Eriksson   +8 more
doaj   +2 more sources

Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors

Platelets, 2022
Chemotherapy-induced thrombocytopenia (CIT) is a common complication in cancer patients, especially after multiple cycles of chemotherapy, which leads to the delayed treatment or reduced dosage.
Yanting Gao, Qi Liu, Yingying Shen, Yuzhu Li, Keding Shao, Baodong Ye, Yiping Shen, Yuhong Zhou, Dijiong Wu   +8 more
doaj   +2 more sources

Signal mining and analysis for adverse events of avatrombopag based on FAERS

陆军军医大学学报
Objective To mine the adverse drug events (ADE) signal of avatrombopag, an effective drug for thrombocytopenia treatment, based on real world data in order to provide reference for its clinical safety application.
XIONG Rui, WANG Jin, YANG Zhen
doaj   +2 more sources